CD274 and breast cancer: Immunomodulation/immunotherapy (either PD1 or PD‐L1 antibody) is a good choice for the patient with PD‐L1‐positive status, and PD‐L1 has been reported as an active immune checkpoint in a variety of cancers including BC.